The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty

Chris Skedgel, Ron Goeree, Sue Pleasance, Kara Thompson, Bernie O'Brien, David Anderson

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)


Although the risk of thromboembolism after total hip arthroplasty continues beyond hospital discharge, the cost-effectiveness of extending prophylaxis beyond hospitalization is unclear. We compared the cost-effectiveness of an extended duration of antithrombotic prophylaxis following total hip arthroplasty, with use of low-molecular-weight heparin or warfarin administered for twenty-eight days beyond hospital discharge, in terms of incremental cost per quality-adjusted life year gained.
Original languageEnglish
Pages (from-to)819-828
Number of pages10
JournalThe Journal of Bone and Joint Surgery (American)
Issue number4
Publication statusPublished - Apr 2007


  • Anticoagulants
  • Arthroplasty, Replacement, Hip
  • Cost-Benefit Analysis
  • Heparin, Low-Molecular-Weight
  • Humans
  • Thromboembolism
  • Time Factors
  • Warfarin

Cite this